Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Kathy Tomashitis, MNS, RD Pediatric Screening Coordinator Division of Women and Childrens Services, SC DHEC
Technological advances: increased use of tandem mass spectrometry (MS/MS) in newborn screening applications and improvement in the screening protocol for cystic fibrosis NO ADDITIONAL BLOOD NEEDED!
Improved morbidity/mortality: research supports improved outcomes for pre-symptomatic identification of cystic fibrosis as well as disorders found through MS/MS; research has long recognized benefit of screening for biotinidase deficiency Cost benefit: research supports pre-symptomatic identification of fatty acid, amino acid and organic acid disorders found through MS/MS
Survey of all newborn health care providers in SC conducted in 11/00: top three conditions recommended for expansion include cystic fibrosis, LCHADD ( a fatty acid oxidation disorder) and biotinidase deficiency Newborn Screening Advisory Committee recommended step-wise expansion to include cystic fibrosis, biotinidase deficiency and disorders found through MS/MS
Newborn Screening ExpansionFatty Acid, Amino Acid and Organic Acid Disorders
Fatty acid, amino acid and organic acid disorders are individually rare, but occur with a combined frequency of 1:5000 to 1:6000 births Screening will include measurement of an acyl carnitine profile and an amino acid profile
Newborn Screening ExpansionFatty Acid, Amino Acid and Organic Acid Disorders
MS/MS is very precise, but interpretation is complex REMINDER--MS/MS can identify many, but not all metabolic disorders
Avoid fasting Immediate medical attention when unable to eat usual diet Control type/amount of fat in diet depending upon the specific diagnosis Carnitine if indicated Cornstarch tube feeding at night if indicated
Ensure immunizations are up-to-date Treat infections promptly All patients should keep an emergency protocol letter with them at all times
Estimated incidence is 1:40,000 to 1:100,000 Outcomes of known patients highly variable, but may be less severe than other FA disorders
Unknown incidence Differential diagnosis needed to separate LCHADD from TFP Cardiomyopathy and retinal changes HELLP/AFLP in 20% of affected pregnancies
Unknown incidence Some infants have cardiomyopathy Good outcome when treated presymptomatically
Not thought to be rare, but incidence unknown Outcomes variable based upon phenotype Riboflavin supplementation useful in some mild cases
Unknown incidence Muscle weakness, pain and myoglobinuria prompted by prolonged exercise 80% affected patients have been male Cardiac dysfunction rare
Avoid fasting Immediate medical attention when unable to eat usual diet Control type/amount of protein in diet depending upon the specific diagnosis Carnitine if indicated
Ensure immunizations are up-to-date Treat infections promptly All patients should keep an emergency protocol letter with them at all times
Estimated incidence is 1:100,000 Oral antibiotics may be useful to decrease gut propionate Biotin if helpful Continuous overnight feeds helpful in some patients
Estimated incidence is 1:48,000 for B-12 nonresponsive type; unknown incidence in other types Oral antibiotics may be useful to decrease gut propionate Vitamin B-12 if helpful Betaine if helpful
Thought to be very rare Long term outcome not clearly known, but appears to be good
Estimated incidence is 1:230,000 Most have sweaty sock odor Glycine may be used in addition to carnitine
Thought to be very rare Long term outcome not clearly known, but appears to be good
Estimated incidence is 1:50,000 Glycine may be used in addition to carnitine NBS result in infant may really be indicative of maternal 3-MCC
Unknown incidence Urinary ketones should be monitored Moderate protein intake indicated Bicarbonate therapy often required long term
Unknown incidence Diet may also be somewhat restricted in fat Supplemental glucose may be used
Thought to be very rare Type II is X-linked Protein restriction and supplemental carnitine may be useful for Type I Other types do not appear to respond to treatment
Estimated incidence is 1:87,000 Diet restriction NOT indicated Most cases are biotin responsive Biotin enhances the function of the carboxylase enzymes Not the same as biotinidase deficiency!
Estimated incidence is 1:40,000 Very important to proceed directly to diagnostic testing with any elevation Must treat fever aggressively Hospital admission mandatory for IVs with any vomiting illness
Prone to subdural hemorrhages and retinal hemorrhages after minor head trauma (ie, fall when learning to walk) Can be misdiagnosed as child abuse May have profuse sweating
Estimated incidence is 1:200,000 Dislocated lens, marfanoid body type, thromboembolism Some patients are vitamin B 6 responsive MET restricted diet if B 6 non-responsive Betaine used after infancy Monitor folate/B 12 and supplement if needed
Estimated incidence is 1:185,000 Severe ketoacidosis, ammonia, sezuires, coma LEU restricted/ILE, VAL controlled diet Thiamin if responsive
Estimated incidence is 1:57,000 ammonia, lethargy, seizures, coma Protein restricted diet, ARG supplementation Na benzoate, Na phenylacetate, Na phenylbutyrate if indicated Aggressive treatment when ammonia levels
Estimated incidence is 1:70,000 ammonia, lethargy, seizures, coma Protein restriction, ARG supplementation Na benzoate, Na phenylacetate, Na phenylbutyrate if indicated Aggressive treatment when ammonia levels